Combined use of microwave ablation and cell immunotherapy induces nonspecific immunity of hepatocellular carcinoma model mice

Duan, Xuhua; Wang, Manzhou; Han, Xinwei; Ren, Jianzhuang; Huang, Guo‐Hao; Ju, Shuguang; Zhang, Qinghui

doi:10.1080/15384101.2020.1853942

Cited by 44 publications

(30 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Using the CT26 tumor model, Liu et al studied the roles of palliative RFA (pRFA) in T-cell immune responses and tumor recurrence, which could be more significant in combination with antibodies (74). Likewise, MWA combined with anti-PD-1/anti-CTLA-4 protected mice from recurrence with improved survival (133).…”

Section: Combined Ablative-immunotherapymentioning

confidence: 99%

Combination of Ablation and Immunotherapy for Hepatocellular Carcinoma: Where We Are and Where to Go

et al. 2021

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related deaths worldwide and is increasing in incidence. Local ablative therapy plays a leading role in HCC treatment. Radiofrequency (RFA) is one of the first-line therapies for early local ablation. Other local ablation techniques (e.g., microwave ablation, cryoablation, irreversible electroporation, phototherapy.) have been extensively explored in clinical trials or cell/animal studies but have not yet been established as a standard treatment or applied clinically. On the one hand, single treatment may not meet the needs. On the other hand, ablative therapy can stimulate local and systemic immune effects. The combination strategy of immunotherapy and ablation is reasonable. In this review, we briefly summarized the current status and progress of ablation and immunotherapy for HCC. The immune effects of local ablation and the strategies of combination therapy, especially synergistic strategies based on biomedical materials, were discussed. This review is hoped to provide references for future researches on ablative immunotherapy to arrive to a promising new era of HCC treatment.

show abstract

Section: Combined Ablative-immunotherapymentioning

confidence: 99%

Combination of Ablation and Immunotherapy for Hepatocellular Carcinoma: Where We Are and Where to Go

et al. 2021

View full text Add to dashboard Cite

show abstract

“…To achieve this goal, systemic chemotherapy, thermal ablation, or chemoembolization could be used. In an animal HCC model the combination of microwave ablation plus anti-PD-1/anti-CTLA-4 enhanced intra-tumoral infiltration of cytotoxic T lymphocytes and extended survival [127]. Although chemotherapy agents are generally considered immunosuppressive, these treatments through tumor cell death promotes the releasing of HCC neo-antigens that could let the priming of HCC-specific CD8 T cell response.…”

Section: Pd-1/pd-l1 Blockade Plus Strategies To Increase Hcc Antigen Presentationmentioning

confidence: 99%

Anti-PD-1/PD-L1 Based Combination Immunotherapy to Boost Antigen-Specific CD8+ T Cell Response in Hepatocellular Carcinoma

Peña-Asensio

Calvo

Torralba

et al. 2021

Cancers

View full text Add to dashboard Cite

Thirty to fifty percent of hepatocellular carcinomas (HCC) display an immune class genetic signature. In this type of tumor, HCC-specific CD8 T cells carry out a key role in HCC control. Those potential reactive HCC-specific CD8 T cells recognize either HCC immunogenic neoantigens or aberrantly expressed host’s antigens, but they become progressively exhausted or deleted. These cells express the negative immunoregulatory checkpoint programmed cell death protein 1 (PD-1) which impairs T cell receptor signaling by blocking the CD28 positive co-stimulatory signal. The pool of CD8 cells sensitive to anti-PD-1/PD-L1 treatment is the PD-1dim memory-like precursor pool that gives rise to the effector subset involved in HCC control. Due to the epigenetic imprints that are transmitted to the next generation, the effect of PD-1 blockade is transient, and repeated treatments lead to tumor resistance. During long-lasting disease, besides the TCR signaling impairment, T cells develop other failures that should be also set-up to increase T cell reactivity. Therefore, several PD-1 blockade-based combinatory therapies are currently under investigation such as adding antiangiogenics, anti-TGFβ1, blockade of other negative immune checkpoints, or increasing HCC antigen presentation. The effect of these combinations on CD8+ T cells is discussed in this review.

show abstract

“…MWA is also a commonly used TA technique for HCC treatment. MWA combined with anti-PD-1/anti-CTLA-4 not only increased the survival time and protected the mice against tumor recurrence, but also enhanced the intratumoral infiltration of CTL and systemic T-cell immune responses induced by MWA through activation of synergistically specific antitumor immunity[ 79 ]. Recently, Leuchte et al [ 80 ] performed a prospective study to observe the immune responses of 23 HCC patients undergoing MWA.…”

Section: Thermal Ablation Combined With Immunotherapymentioning

confidence: 99%

Thermal ablation and immunotherapy for hepatocellular carcinoma: Recent advances and future directions

Bo¹,

Sun²,

Yu³

et al. 2021

WJGO

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is one of most common cancers that cause death in the world. Thermal ablation (TA) is an important alternative treatment method for HCC patients who are not appropriate for surgery or liver transplantation. Particularly for small and early HCCs, TA can be considered as the first-line curative treatment. However, local and distant recurrence rates are still high even though the TA equipment and technology develop rapidly. Immunotherapy is a novel systemic treatment method to enhance the anti-tumor immune response of HCC patients, which has the potential to reduce the tumor recurrence and metastasis. The combination of local TA and systemic immunotherapy for HCCs may be an ideal treatment for enhancing the efficacy of TA and controlling the recurrence. Herein we summarize the latest progress in TA, immunotherapy, and their combination for the treatment of patients with HCC and discuss the limitations and future research directions of the combined therapy.

show abstract

Combined use of microwave ablation and cell immunotherapy induces nonspecific immunity of hepatocellular carcinoma model mice

Cited by 44 publications

References 29 publications

Combination of Ablation and Immunotherapy for Hepatocellular Carcinoma: Where We Are and Where to Go

Combination of Ablation and Immunotherapy for Hepatocellular Carcinoma: Where We Are and Where to Go

Anti-PD-1/PD-L1 Based Combination Immunotherapy to Boost Antigen-Specific CD8+ T Cell Response in Hepatocellular Carcinoma

Thermal ablation and immunotherapy for hepatocellular carcinoma: Recent advances and future directions

Contact Info

Product

Resources

About